Ozempic vs Wegovy vs Zepbound vs Mounjaro: Cost, Coverage, and Real Weight Loss in 2026
Ozempic, Wegovy, Zepbound, and Mounjaro are the four GLP-1 medications driving the largest prescription weight-loss market in pharmaceutical history. Two contain semaglutide (Ozempic and Wegovy, both Novo Nordisk), and two contain tirzepatide (Mounjaro and Zepbound, both Eli Lilly). The pairs are chemically identical within each pair but differ in FDA-approved indication, packaging, and how insurance pays for them. This guide explains the practical differences a cash-pay or insured patient should care about in 2026.
- › Ozempic and Mounjaro are FDA-approved for diabetes; Wegovy and Zepbound are FDA-approved for weight loss. Chemistry is identical within each pair.
- › Cash prices: Ozempic $1,000-$1,150, Wegovy $1,350 ($499 with savings card), Mounjaro $1,100, Zepbound $1,060 ($349-$549 LillyDirect vials).
- › Tirzepatide (Mounjaro/Zepbound) produces 5-7 percentage points more weight loss than semaglutide in head-to-head trial comparisons.
- › Insurance covers Ozempic/Mounjaro for diabetes widely; Wegovy/Zepbound for obesity in only 30-40% of large employer plans.
- › LillyDirect Zepbound vials at $349-$549/month are the cheapest legitimate brand-name self-pay option in 2026.
The Four Medications at a Glance
Semaglutide (Novo Nordisk): - Ozempic: FDA-approved for type 2 diabetes, not for weight loss. Cash price approximately $1,000 to $1,150 per month. - Wegovy: FDA-approved for chronic weight management at BMI 30+ or BMI 27+ with comorbidity. Cash price approximately $1,350 per month.
Tirzepatide (Eli Lilly): - Mounjaro: FDA-approved for type 2 diabetes, not for weight loss. Cash price approximately $1,100 per month. - Zepbound: FDA-approved for chronic weight management at the same BMI thresholds as Wegovy. Cash price approximately $1,060 per month (LillyDirect self-pay vial program is lower).
The chemistry is identical within each pair. The difference is regulatory: insurance plans that cover diabetes but not obesity medications will pay for Ozempic or Mounjaro but deny Wegovy or Zepbound, even though the active drug is the same.
Average Weight Loss in Clinical Trials
Semaglutide (STEP-1 trial, 68 weeks, 2.4mg weekly): mean weight loss of 14.9 percent of body weight, compared to 2.4 percent on placebo. For a 250-pound starting patient, that is approximately 37 pounds lost over 68 weeks.
Tirzepatide (SURMOUNT-1 trial, 72 weeks, 15mg weekly): mean weight loss of 20.9 percent of body weight on the highest dose, with the 10mg dose producing 19.5 percent and 5mg producing 15.0 percent. For a 250-pound starting patient on 15mg, that is approximately 52 pounds lost over 72 weeks.
Real-world results in the cash-pay telehealth setting tend to underperform the trial averages by 20 to 40 percent because patients escalate doses more slowly, skip doses due to side effects, and stop sooner. Realistic expectation: 8 to 12 percent loss on semaglutide and 12 to 18 percent on tirzepatide in patients who complete 12 months of treatment.
Cash-Pay Cost Comparison 2026
Without insurance, monthly cash costs as of Q1 2026: - Ozempic: $1,000 to $1,150 (rarely paid cash; prescribed for diabetes with coverage) - Wegovy: $1,350 standard pharmacy, $499 through Novo Nordisk WeGoTogether savings card for self-pay (cap 6 months) - Mounjaro: $1,100 standard pharmacy - Zepbound: $1,060 standard, $349 to $549 through LillyDirect Self Pay vial program (single-dose vials, lower than auto-injector pens)
The LillyDirect Zepbound vial program launched in 2024 specifically to compete with compounded tirzepatide. At $349 for the 2.5mg starting dose and $499 for the 5mg and 7.5mg doses, it is the cheapest brand-name GLP-1 self-pay option available.
Compounded semaglutide and tirzepatide became substantially harder to access after the FDA removed both drugs from the shortage list in 2024 to 2025. See our separate guide on the legal status of compounded GLP-1s for the current landscape.
Insurance Coverage Patterns
Insurance coverage in 2026 follows a strict pattern: diabetes coverage is widespread, obesity coverage is restricted.
Most commercial plans, Medicare Part D, and Medicaid cover Ozempic and Mounjaro for documented type 2 diabetes (A1C above 6.5 or equivalent). Prior authorization is routine but approval rates exceed 80 percent when criteria are met.
Wegovy and Zepbound coverage for obesity (without diabetes) is far less common. Approximately 30 to 40 percent of large employer plans cover GLP-1s for weight loss in 2026, up from under 20 percent in 2023. Medicare specifically excludes weight-loss medications by federal statute, though there is ongoing legislative effort to change this. Medicaid coverage varies by state.
The practical implication: patients with diabetes who also want weight loss are best served by Ozempic or Mounjaro under their diabetes coverage. Patients without diabetes seeking weight loss often face full cash pricing for Wegovy or Zepbound unless their employer has specifically added obesity coverage.
Side Effects and Tolerability
All four medications share the GLP-1 class side-effect profile: nausea, vomiting, diarrhea, constipation, and (less commonly) gallbladder issues, pancreatitis, and gastroparesis. Side effects are dose-dependent and typically peak during dose escalation.
Tirzepatide is generally better tolerated than semaglutide at clinically effective doses, likely because of the dual GIP/GLP-1 mechanism. SURMOUNT-1 reported 4.3 percent discontinuation for adverse events on tirzepatide 15mg versus 6.4 percent in STEP-1 for semaglutide 2.4mg.
The most common side effect causing discontinuation is severe nausea during dose escalation. Slow titration (extra weeks at each dose level) substantially improves tolerance. Patients who experience severe symptoms on semaglutide sometimes tolerate tirzepatide better, and vice versa.
Which One Should You Choose?
For patients with type 2 diabetes seeking weight loss: Mounjaro is generally preferred over Ozempic because tirzepatide produces approximately 5 to 7 percentage points more weight loss at equivalent diabetes control. Both are widely covered by diabetes insurance benefits.
For patients with obesity seeking weight loss, with insurance that covers GLP-1s for obesity: Zepbound is generally preferred over Wegovy for the same efficacy reason.
For cash-pay patients without insurance: Zepbound through LillyDirect at $349 to $549 per month is the cheapest legitimate brand-name option. Wegovy at $499 through Novo Nordisk savings card is comparable for the first 6 months. Beyond that period, Zepbound LillyDirect remains the most affordable brand pathway.
For patients with severe nausea on one medication: switching from semaglutide to tirzepatide (or the reverse) is medically appropriate and often improves tolerance.
Long-Term Use and Discontinuation
All four medications are intended for long-term use. The STEP-4 and SURMOUNT-4 trials showed that discontinuing either drug results in approximately two-thirds of lost weight returning within 12 months. Maintenance dosing strategies (lower doses every 1 to 2 weeks) are being studied but are not yet established standard of care.
Long-term cost is the dominant practical question. A patient who needs 10 years of GLP-1 therapy at $500/month is facing $60,000 in lifetime medication costs without insurance. Many patients reduce frequency (every 10 to 14 days at maintenance) or transition to lower doses once goal weight is achieved, both of which lower long-term cost but require physician supervision.
Frequently Asked Questions
Is Zepbound the same as Mounjaro? +
Yes, both contain tirzepatide as the active ingredient. Zepbound is FDA-approved for chronic weight management; Mounjaro is FDA-approved for type 2 diabetes. The medication is chemically identical, but they are sold separately because of how insurance covers diabetes versus obesity.
Is Wegovy the same as Ozempic? +
Yes, both contain semaglutide. Wegovy is FDA-approved for weight management at higher doses (up to 2.4mg weekly); Ozempic is FDA-approved for type 2 diabetes at lower doses (typically up to 1mg or 2mg weekly). Same drug, different doses and indications.
Which GLP-1 produces the most weight loss? +
In head-to-head trials, tirzepatide (Mounjaro/Zepbound) produces approximately 20 to 21 percent body weight loss on the highest doses, compared to 15 percent for semaglutide (Ozempic/Wegovy). For most patients, tirzepatide is more effective per milligram.
What is the cheapest brand-name GLP-1 in 2026? +
LillyDirect Zepbound self-pay vials at $349 (2.5mg starter) to $549 (10mg and higher) per month. Novo Nordisk WeGoTogether savings card brings Wegovy to $499/month for up to 6 months. Beyond those programs, no brand-name GLP-1 is under $1,000/month at retail.
Will my insurance cover Wegovy or Zepbound? +
Approximately 30 to 40 percent of large employer commercial plans cover GLP-1s for obesity in 2026. Medicare specifically excludes weight-loss medications. Medicaid varies by state. Coverage for diabetes (Ozempic/Mounjaro) is much more common (80 percent+ of plans).
Can I switch between these medications? +
Yes, switching between semaglutide and tirzepatide is medically appropriate and often improves tolerance for patients with severe side effects. Switching within a pair (Ozempic to Wegovy, or Mounjaro to Zepbound) is usually about insurance coverage rather than medical reasons, since the drug is the same.
How long do I need to stay on a GLP-1? +
Clinical evidence suggests indefinite or very long-term use. Discontinuation studies show approximately two-thirds of lost weight returns within 12 months of stopping. Maintenance dosing strategies (lower doses, less frequent injections) are being studied but not yet standard.
Bottom Line
For most patients in 2026, the choice between these four medications comes down to insurance coverage and your starting indication. Diabetes patients should default to Mounjaro for weight loss benefit. Obesity patients with coverage should default to Zepbound for the same reason. Cash-pay patients without insurance should investigate LillyDirect Zepbound vials at $349 to $549/month as the cheapest legitimate brand-name option. All four medications are clinically effective; the decision is largely economic in 2026.
Sources
- Wilding JPH, et al. STEP-1 Trial: Semaglutide 2.4 mg in Adults with Overweight or Obesity. N Engl J Med, 2021. (Semaglutide weight loss efficacy)
- Jastreboff AM, et al. SURMOUNT-1 Trial: Tirzepatide Once Weekly for Treatment of Obesity. N Engl J Med, 2022. (Tirzepatide weight loss efficacy)
- FDA prescribing information for Ozempic, Wegovy, Mounjaro, and Zepbound. Current label 2026. (Indications and dosing)
- LillyDirect Self Pay program (lillydirect.lilly.com), Q1 2026 pricing. (Self-pay vial program pricing)